期刊文献+

羟丙基-β-环糊精对西罗莫司的增溶作用研究 被引量:3

Solubilization Effect of Hydroxypropyl-β-cyclodextrin on Sirolimus
原文传递
导出
摘要 目的研究羟丙基-β-环糊精包合对难溶于水的西罗莫司溶解度的增强作用。方法采取超声法制备西罗莫司-羟丙基-β-环糊精包合物,用相溶解度法考察羟丙基-β-环糊精的增溶能力,以X射线衍射法、傅立叶红外光谱法、差示扫描量热法验证包合物的形成。结果西罗莫司与羟丙基-β-环糊精形成了包合物,在25℃条件下,随着羟丙基-β-环糊精浓度的增加,西罗莫司的溶解度由1.18 mg·L-1上升到118.15 mg·L-1,提高了约100倍。结论羟丙基-β-环糊精的包合技术能显著提高西罗莫司的溶解度。 OBJECTIVE To investigate the enhancement of dissolution of sirolimus by its complexation with hydroxy- propyl-β-cyclodextrin. METHODS The inclusion complexes of sirolimus were prepared by ultrasonic method. The solubilizing power of hydroxypropyl-β-cyclodextrin were determined by phase solubility technique. X-ray diffraction(XRD), Fourier transform infrared spectroscopy(FT-IR) and differential scanning calorimetry(DSC) were used to verify the formation of inclusion complexes. RESULTS Sirolimus and hydroxypropyl-β-cyclodextrin formed inclusion complexes. At 25 ℃, with hydroxypropyl-β-cyclodextrin concentration increased, the solubility of sirolimus rised from 1.18 mg.L^-1 up to 118.15 mg·L^-1, increased 100 times approximately. CONCLUSION Hydroxypropyl-β-cyclodextrin inclusion technology can rise the solubility of sirolimus significantly.
出处 《中国现代应用药学》 CAS CSCD 2012年第12期1116-1120,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 西罗莫司 羟丙基-Β-环糊精 包合 sirolimus hydroxypropyl-β-cyclodextrin inclusion
  • 相关文献

参考文献4

二级参考文献34

  • 1谷福根,高永良,崔福德.环糊精包合物研究进展[J].中国新药杂志,2005,14(6):686-693. 被引量:47
  • 2金小江,周建平.环糊精包合特性及包合常数的测定和预测[J].药学进展,2005,29(11):491-497. 被引量:26
  • 3Guba M, van Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis : involvement of vascular endothelial growth factor. Nat Med, 2002, 8 ( 2 ) : 125-135.
  • 4Kerjaschki D. How to control lymphangiogenesis : a novel role for rapamycin. Kidney Int, 2007, 71(8) :717-719.
  • 5Petrieoin EF 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping:akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res, 2007, 67(7) :3431-3440.
  • 6Kobavashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhabitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci, 2007, 98 (5) : 726-733.
  • 7Granville CA, Warfel N, Tsurutani J, et al. Identification of a highly effective rapamycin schedule that markedlyreduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res, 2007, 13(7) :2281-2289.
  • 8Raught B, Gingras AC, Sonenberg N. The target of rapamycin(TOR) proteins. Proc Natl Acad Sci USA, 2001,98 (13) :7037-7044.
  • 9Marignol L, Coffey M, Lawler M, et al. Hypoxia in prostate eaneer:a powerful shield against tumour destruction? Cancer Treat Rev, 2008, 34(4) :313-327.
  • 10Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factorl alpha expression and function by themammalian target of rapamycin. Mol Cell Biol, 2002, 22(20) :7004-7014.

共引文献19

同被引文献53

  • 1李丽华,焦亿,焦映棋.艾连挥发油β-环糊精包合物稳定性考察[J].中医药学报,2011,39(4):76-78. 被引量:4
  • 2白晓艳,赵忠喜.柳蒿芽中黄酮类化合物提取条件及抗氧化作用研究[J].呼伦贝尔学院学报,2013,21(2):105-107. 被引量:9
  • 3崔福德.药剂学[M].5版.北京:人民卫生出版社,2005:202.
  • 4中国药典.二部[S].2010:附录196.
  • 5Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of canner with rapamycin derivatives [J]. Ann Oncol, 2005, 16 (4):525- 537.
  • 6Spilman P, Podlutskaya N, Hart MJ,et al. Inhibition of mTOR by rapamycin abblishes cognitive deficits and reduces amyloid-beta levels in amouse model of Alzheimer' s disease [ J ]. PLoS One, 2010, 5 (4) : e9979.
  • 7Emami S, Valizadeh H, Islambulchilar Z, et al. Development and Physicochemical Characterization of Sirolimus Solid Dispersions Prepared by Solvent Evaporation Method[ J], Adv Pharm Bull, 2014, 4 (4) : 369-374.
  • 8Park SM, Kim MS, Park SJ, et al. Novel temperature-triggered liposome with high stability: Formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU) [ J ]. J Control Release, 2013,170(3) :373-379.
  • 9Fu J, Wang D, Wang T, et al. High Entrapment Efficiency of Chitosan/Polylactic Acid/Tripolyphotspate Nanosized Microcapsules for Rapamycin by an Emulsion-Evaporation Approach [ J ]. J Biomed Nanotechnol, 2010, 6(6): 725-728.
  • 10Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability[ J]. Int J Pharm, 2010, 394( 1-2 ) : 179185.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部